3 results about "Methicillin resistance" patented technology

Methods of treating preventing and / or substantially reducing a Pseudomonas aeruginosa (PA) infection and / or a Staphylococcus aureus (SA) infection by administration of a bivalent protein subunit-based vaccine are described. The vaccine can protect subjects with a prior history of exposure to SA from a new exposure to PA or SA, including methicillin resistant SA (MRSA), as well as being able to protecting with no prior exposure to a SA infection. Vaccine formulations are also described.

A method of making a supplemented wound dressing including preparing a coffee extract with or without cardamom and supplementing the wound dressing with the coffee extract is provided. The coffee beans may be Khulani coffee beans and they may be green coffee beans, lightly roasted coffee beans, or medium roasted coffee beans. The supplemented wound dressing prepared according to this method is effective to inhibit bacterial growth, particularly growth of methicillin-resistant Staphylococcus aureus.

The present application belongs to the field of pharmaceutical chemistry and antibacterial drug technology, and particularly relates to a C14 modified pleuromutilin derivative, a preparation method thereof and application thereof in treating gram-positive bacteria, especially gram-positive drug-resistant bacterial infection. The C14 modified pleuromutilin derivative provided by the present application has a structure shown in formula I or formula II. The present application introduces a heterocyclic side chain (4-trifluoromethylphenylthiol or 1-(4,5-dihydrothiazole-2-yl)azetidine-3-thiol) at the C14 site of pleuromutilin to synthesize the C14 modified pleuromutilin derivative, which significantly enhances the antibacterial activity of the C14 modified pleuromutilin derivative on methicillin-resistant Staphylococcus aureus (MRSA) and cfr gram-positive bacterial strains, and has high drug resistance barrier, low cytotoxicity and hemolyticity. The C14 modified pleuromutilin derivative provided by the present application is suitable for treating multiple drug-resistant bacterial infection in veterinary and human medicine. Formula I, formula II.